# Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients

Source: https://onco.cc/trials/nct05929885/  
OnCo record `nct05929885` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in pancreatic cancer, run by National Cancer Centre, Singapore, now recruiting.

## Summary

Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients is a phase 2, interventional study registered as NCT05929885 by National Cancer Centre, Singapore, with a registry enrolment figure of 50 participants, started 2023-08-30 and due to reach its primary completion in 2027-02-28. Interventions recorded: Low Dose OXIRI (LD-OXIRI). Conditions listed: Metastatic Pancreatic Cancer. Primary outcome: Overall Response Rate (ORR).; Clinical Benefit Rate (CBR).; The Grade 3-5 Toxicity Rate.. Pancreatic eligibility wording from the registry: "Histopathological diagnosis of pancreatic cancer". Sites: Singapore. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT05929885
- Phase: 2
- Setting: A Phase II Study of Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients.
- Sponsor: National Cancer Centre, Singapore
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05929885: https://clinicaltrials.gov/study/NCT05929885

## Connected records

- cancers: [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05929885.json